<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03869775</url>
  </required_header>
  <id_info>
    <org_study_id>ErzincanU</org_study_id>
    <nct_id>NCT03869775</nct_id>
  </id_info>
  <brief_title>Perfusion Index Changes in Cardiovascular Autonom Neuropathia Type-2 Dm Whit Spinal Anesthesia</brief_title>
  <acronym>PI</acronym>
  <official_title>Observational Study Relationship Between Perfusion Index Changes and Intraoperative Complications in Cardiovascular Autonom Neuropathia Type-2 DM Patients With Spinal Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erzincan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erzincan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular autonomic neuropathy in diabetic patients, hypertension, sympathovagal
      imbalance, orthostatic hypotension, painless myocardial infarction, ischemia, left
      ventricular dysfunction, cardiac sympathetic and parasympathetic innervation disturbances, qt
      interval prolongation and sudden deaths observed. The purpose of this study is to evaluate
      the relationship between cardiovascular autonomic neuropathy and perfusion index in spinal
      anesthesia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular autonomic neuropathy in diabetic patients, hypertension, sympathovagal
      imbalance, orthostatic hypotension, painless myocardial infarction, ischemia, left
      ventricular dysfunction, cardiac sympathetic and parasympathetic innervation disturbances, qt
      interval prolongation and sudden deaths observed. The purpose of this study is to evaluate
      the relationship between cardiovascular autonomic neuropathy and perfusion index in spinal
      anesthesia
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Perfusion index change</measure>
    <time_frame>Day 1</time_frame>
    <description>Perfusion index change in spinal anesthesia related cardiovascular autonom neuropatia</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Anesthesia; Adverse Effect</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>no additional disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>working group-1</arm_group_label>
    <description>additional disease only DM and no cardıovascular autonomous neuropathıa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>working group-2</arm_group_label>
    <description>additional disease only DM and pozitif cardıovascular autonomous neuropathıa</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>perfusion index monitor</intervention_name>
    <description>perfusion index measured in patients undergoing spinal anesthesia with non-invasive perfusion index monitor</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>working group-1</arm_group_label>
    <arm_group_label>working group-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ewing test</intervention_name>
    <description>ewing tests will be applied to diabetic patients undergoing spinal anesthesia for cardıovascular autonomous neuropathıa diagnosis</description>
    <arm_group_label>working group-1</arm_group_label>
    <arm_group_label>working group-2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients over 18 years old
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the patient will be operated with spinal anesthesia

          -  over 18 years

          -  no additional disease and only DM

        Exclusion Criteria:

          -  patients with additional disease

          -  patients under 18 years of age

          -  patients contraindicated in spinal anesthesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>FARUK SUBAŞI</last_name>
    <phone>5414247924</phone>
    <email>dr.faruksubasi@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erzincanu</name>
      <address>
        <city>Erzincan</city>
        <state>Merkez</state>
        <zip>24050</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FARUK SUBAŞI</last_name>
      <phone>5414247924</phone>
      <email>dr.faruksubasi@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>March 10, 2019</last_update_submitted>
  <last_update_submitted_qc>March 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erzincan University</investigator_affiliation>
    <investigator_full_name>faruk subasi</investigator_full_name>
    <investigator_title>Asistant Doctor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

